Another week, another twist in the turnaround efforts at Novo Nordisk, the maker of the blockbuster Ozempic and Wegovy weight ...
Dive deeper with STAT+. Gain unlimited access to expert analysis, newsletters, events, and news alerts.
A new analysis finds that the heart-protecting benefits of semaglutide are largely independent of its weight loss effects.
Shares of Eli Lilly and Novo Nordisk fell Friday, Oct. 17 after Pres. Donald Trump said the price of the weight-loss drug Ozempic could soon drop to $150 a month.
17h
How did Charles Barkley lose weight? Explaining how much loss led to Shaq calling him a 'sex symbol'
"Charles Barkley is going on the offense after seeing his weight rebound. The NBA Hall of Famer has signed on as GLP-1 ...
Novo Nordisk (NVO) recruits top healthcare analyst Michael Novod, a long time bull of the company, as head of its investor ...
Once-weekly semaglutide 2.4 mg conferred a greater reduction in major adverse cardiovascular events than placebo, regardless ...
Karen Finerman, CEO & Co-founder, Metropolitan Capital Advisors, said in a recent program on CNBC that she likes NVO amid the ...
Novo Nordisk Chairman Helge Lund is stepping down after clashing with the company’s main shareholder, the Novo Nordisk ...
() -London-based startup SheMed, which offers personalized weight-loss plans using popular medicines Wegovy and Mounjaro, said on Thursday it has raised $50 million in its Series A funding round to ...
An analysis found that a shrinking waist size was responsible for only around a third of the cardiovascular benefits in ...
The Trump administration is preparing a new probe into drug-pricing practices among U.S. trading partners, laying the ground ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback